Document Detail


In vivo inhibition of platelet aggregation and occlusive coronary thrombus formation by a new calcium antagonist (R023-6152).
MedLine Citation:
PMID:  1724526     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Reports have shown that all three major classes of calcium antagonists can inhibit platelet aggregation in vitro. In this study, we compared the platelet antiaggregatory effects of R023-6152, a thiazepinone-type calcium antagonist, with diltiazem in an in vivo canine model of spontaneous coronary thrombosis. Plasma serotonin (5-HT) levels measured in the coronary sinus were used as an index of in vivo platelet aggregation and coronary flow measured by a Doppler flow probe. Untreated controls developed total coronary occlusion in 62 +/- 18 min after the current used to initiate thrombus formation was discontinued. Control 5-HT levels peaked at 213 +/- 63 ng/ml just before occlusion. Dogs receiving intravenous (i.v.) R023-6152 (200 micrograms/kg) or diltiazem (50 micrograms/kg) immediately after the current was discontinued exhibited no significant elevations in 5-HT values (12.3 +/- 1.4 and 1.84 +/- 0.42 ng/ml for R023-6152 and diltiazem, respectively) or development of coronary occlusions in the next 3 h. Small, transient decreases in arterial pressure (8-10 mm Hg) and changes in contractility occurred during infusion of both drugs. Gravimetric determinations of thrombus weights showed significantly smaller thrombi in the drug-treated animals as compared with controls. The results indicate that both R023-6152 and diltiazem are effective in suppressing in vivo platelet aggregation associated with occlusive coronary thrombus formation.
Authors:
L A Sordahl; K A Rex; C R Benedict
Related Documents :
24909796 - Phospholipase d is a central regulator of collagen i-induced cytoskeletal rearrangement...
17635726 - Platelet genomics and the risk of atherothrombosis.
12690916 - The impact of platelet glycoprotein iiia and ia polymorphisms in cardiovascular thrombo...
11192476 - Monitoring antiplatelet therapy: what is the best method?
2881786 - Adrenaline infusion evokes increased thromboxane b2 production by platelets in healthy ...
17378736 - Clustered components of the metabolic syndrome and platelet counts in japanese females.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  18     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1991 Oct 
Date Detail:
Created Date:  1992-04-07     Completed Date:  1992-04-07     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  504-10     Citation Subset:  IM    
Affiliation:
Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston 77550.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Blood Pressure / drug effects
Calcium Channel Blockers / pharmacology*
Coronary Thrombosis / physiopathology,  prevention & control*
Diltiazem / analogs & derivatives*,  pharmacology
Dogs
Electrocardiography
Female
Fibrinolytic Agents / pharmacology*
Heart Rate / drug effects
Male
Platelet Aggregation / drug effects*
Platelet Aggregation Inhibitors / pharmacology*
Rheology
Serotonin / blood
Grant Support
ID/Acronym/Agency:
HL 34837/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Calcium Channel Blockers; 0/Fibrinolytic Agents; 0/Platelet Aggregation Inhibitors; 108383-96-6/RO 23-6152; 42399-41-7/Diltiazem; 50-67-9/Serotonin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Combination therapy with lovastatin and guar gum versus lovastatin and cholestyramine in treatment o...
Next Document:  Effects of some inorganic divalent cations and protein kinase C inhibitors on endothelium-dependent ...